Clinical Trials Logo

Clinical Trial Summary

This randomized, observer-blinded, placebo-controlled, single and multiple ascending-dose study will be conducted in two parts to evaluate the safety, pharmacokinetics, and immunogenicity of BITS7201A. Part A will be an ascending, single-dose, sequential-group study where participants will be randomly assigned to active drug or placebo. Part B will be an ascending, multiple-dose, sequential-group study where participants will be randomized to active drug or placebo. Total length of the study is anticipated to be approximately 12 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02748642
Study type Interventional
Source Genentech, Inc.
Contact
Status Completed
Phase Phase 1
Start date April 7, 2016
Completion date June 14, 2017